About Us
Welcome and thank you for visiting the Amarin in Europe website
At Amarin, we are committed to improving the lives of high-risk cardiovascular patients across Europe by establishing a new treatment for cardiovascular disease.
Cardiovascular disease management, and more specifically residual cardiovascular risk is core to everything we do at Amarin. Through our dedicated research into these areas, we are introducing new alternatives that can offer a better quality of life for our patients.
Throughout Europe, cardiovascular disease is an increasingly common health problem, and one that is growing more serious by the day. That’s why we have made it our mission to improve treatment for those at risk of suffering a stroke, heart attack or similar serious cardiovascular events. The time has come for a systematic change in how this disease is treated, and at Amarin, our goal is to be part of the solution.
Patients across Europe – both now and in the future – are relying on us more than ever to do the right thing. For cardiovascular disease patients, each day brings new worries about the effects of the disease not only on their own lives, but also on those of their families and loved ones.
Amarin has strong roots in Europe, having first established the company here in 1989. Today, as we expand across the continent, we’re focussing our efforts and dedication more than ever on driving a new paradigm in cardiovascular disease management, and addressing cardiovascular risk for patients across the globe.
Amarin Company Profile
Founded in the UK in 1989, Amarin has maintained strong roots in Europe for over 30 years, constantly evolving and innovating to become an industry leader in cardiovascular care.
During this time, Amarin has expanded as a business, becoming one of the foremost companies in the field of cardiovascular therapies. Today we employ over 1,000 people and hold international offices in Bridgewater, New Jersey, Dublin, Ireland, and Zug, Switzerland.
As part of our mission to reduce the burden of cardiovascular disease, we are now opening a new chapter in our company history as we continue to expand across Europe.